〔11〕魏伟,吴希美,李元建. 药理实验方法学〔M〕. 4 版.
北京:人民卫生出版社,2010.
〔12〕BREIMER D D,SCHELLENS J H. A "Cocktail" Strategy
to Assess in vivo Oxidative Drug Metabolism in Humans〔J〕.
Trends Pharmacol Sci,1990,11(6):223-225.
〔13〕GOH B C,REDDY N J,DANDAMUDI U B,et al. An
Evaluation of the Drug Interaction Potential of Pazopanib,
an Oral Vascular Endothelial Growth Factor Receptor
Tyrosine Kinase Inhibitor,Using a Modified Cooperstown
5+1 Cocktail in Patients with Advanced Solid Tumors〔J〕.
Clin Pharmacol Ther,2010,88(5):652-659.
〔14〕MORI K,HASHIMOTO H,TAKATSU H,et al. Cocktail-
Substrate Assay System for Mechanism-Based Inhibition
of CYP2C9,CYP2D6,and CYP3A Using Human Liver
Microsomes at an Early Stage of Drug Development〔J〕.
Xenobiotica,2009,39(8):415-422.
〔15〕BOGAARDS J J,BERTRAND M,JACKSON P,et al. De⁃
termining the Best Animal Model for Human Cytochrome
P450 Activities:A Comparison of Mouse,Rat,Rabbit,
Dog,Micropig,Monkey and Man〔J〕. Xenobiotica,2000,
30(12):1131-1152.
〔16〕MAGGO S D S,SAVAGE R L,KENNEDY M A. Impact of
New Genomic Technologies on Understanding Adverse
Drug Reactions〔J〕. Clin Pharmacokinet,2016,55(4):
419-436.
〔17〕莫延红,牛璇,张兆辉. CYP2C19基因多态性对临床
常见药物代谢的影响〔J〕. 卒中与神经疾病,2019,26
(4):499-507.
〔18〕魏晓冬,张峰,李娟,等. CYP3A4 基础与临床研究进
展〔J〕. 现代生物医学进展,2014,14(11):2180-2182.